^
Association details:
| Biomarker: | ARID1A mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ARID1A, ARID1B, and ARID2 Mutations Serve as Potential Biomarkers for Immune Checkpoint Blockade in Patients With Non-Small Cell Lung Cancer
Published date:
08/26/2021
Excerpt:
Six reported cohorts, a total of 3416 patients, were used to analyze the mutation status of ARID1A, ARID1B, ARID2 and SMARCA4 in patients with NSCLC and the effect of mutations on prognosis after ICIs....Patients with an ARID1A or ARID1B mutation treated with ICIs had a median OS (mOS) of 21 months compared to 11 months for the WT group. Patients with an ARID2 mutation treated with ICIs had an mOS of 36 months compared to 11 months for the WT group...The results of this study demonstrated that patients with ARID1A, ARID1B, or ARID2 mutations were more likely to benefit from ICIs.
DOI:
https://doi.org/10.3389/fimmu.2021.670040
Source:
Title:
TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer
Published date:
09/17/2021
Excerpt:
The top five altered genes, namely, ARID1A, ZFHX3, ATM, ARID2, and NTRK3, were named AZAAN. Therefore, we evaluated the effect of the predictor-AZAAN on responsive stratification in patients who had received immunotherapy. The results indicated that patients harboring AZAAN(+) received more OS benefits from immunotherapy than those patients harboring AZAAN(−) [AZAAN(+) vs. AZAAN(−): 22 months vs. 10 months, log-rank P value = 0.0006, HR = 0.59]...
DOI:
https://doi.org/10.3389/fimmu.2021.732125
Test:
Source:
Title:
Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer
Published date:
08/13/2020
Excerpt:
Mutations in ARID1A and ARID1B were confirmed to be associated with sensitivity to ICIs. Patients harboring these mutations were found to have a better response to treatment (ARID1A: P = 0.045; ARID1B: P = 0.034) and prolonged progression-free survival (ARID1B: P = 0.032)....ARID1A and ARID1B could serve as novel biomarkers for the prognosis and sensitivity to ICIs of advanced NSCLC.
DOI:
10.1186/s10020-020-00208-9
Source:
Title:
A pan-cancer analysis of ARID1A as a potential biomarker for immune checkpoint therapy.
Published date:
05/13/2020
Excerpt:
CONTRADICTING EVIDENCE:...the TMB level and prognositic analysis were performed on patients in two independent NSCLC cohorts with ICIs...The overall survival (OS) of ARID1A mutation group were significantly shorter than wild-type group (OS, median, 6.80 vs 10.28 months; HR, 1.47; P = 0.0474)...
DOI:
10.1200/JCO.2020.38.15_suppl.3540
Source:
Title:
ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy
Excerpt:
...ARID1A alterations (>5% of prevalence in this cohort): non-small cell lung cancer, colorectal adenocarcinoma, breast cancer, melanoma, pancreatic ductal adenocarcinoma, cholangiocarcinoma/hepatocellular carcinoma, gastric/esophageal adenocarcinoma, uterine/ovary endometrial (endometrioid) carcinoma (including clear-cell carcinoma), and urothelial bladder carcinoma....Median progression-free survival (PFS) after checkpoint blockade immunotherapy was significantly longer in the patients with ARID1A-altered tumors (n=46) than in those with ARID1A wild-type tumors (n=329) (11 months vs 4 months, p=0.006)….
DOI:
http://dx.doi.org/10.1136/jitc-2019-000438
